Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

AbbVie (NY: ABBV )

158.02 +2.72 (+1.75%)
Official Closing Price Updated: 7:00 PM EDT, Mar 24, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about AbbVie

< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Johnson & Johnson: Taking The Bull By The Horns?
Johnson & Johnson is rushing toward a patent cliff but a new shelf offering registration suggests itis gearing up for acquisitions. 
Via MarketBeat
Topics Intellectual Property Regulatory Compliance
Exposures Intellectual Property Legal Regulatory
3 Top Dividend Kings to Buy for the Long Haul
These companies have more than 150 years of dividend growth between them. 
Via The Motley Fool
3 Dividend Stocks That Should Pay You the Rest of Your Life
Each of these companies can provide income investors with growing, market-beating passive income. 
Via The Motley Fool
MarketBeat Week in Review – 2/13 - 2/17
Retail sales were up but so was inflation which meant more volatility for stocks. Enjoy your holiday weekend and catch up on our most read stories this week 
Via MarketBeat
Topics Economy
Exposures Interest Rates
Where AbbVie Stands With Analysts
 
Via Benzinga
If You Invested $100 In This Stock 10 Years Ago, You Would Have $400 Today
 
Via Benzinga
AbbVie (ABBV) Q4 2022 Earnings Call Transcript
ABBV earnings call for the period ending December 31, 2022. 
Via The Motley Fool
3 Stocks At An Inflection Point
With consumer and producer prices surprising to the upside, multiple research outlets are starting to call for more aggressive Fed ... 
Via Benzinga
2 Exceptional Growth Stocks to Buy Before the Next Bull Market
Both of these companies have long runways for growth and catalysts on the way. 
Via The Motley Fool
How Abbott Labs, AbbVie Could Profit on Seizure Drug Formula
New research suggests Depakote ingredient could have a new clinical function. This could present more profit potential for drugmakers as well as investors. 
Via MarketBeat
3 Exceptional Dividend Stocks to Buy Right Now
These stocks can add to your returns -- no matter what the stock itself or the general market is doing. 
Via The Motley Fool
These 2 Growth Stocks Are Easily Defying the Bear Market
Impressively, neither company is predicting rapid growth. 
Via The Motley Fool
Is This the Start of a Nightmare for AbbVie Stock?
With a competitor set to devour market share, stormy waters might be ahead. 
Via The Motley Fool
3 Defensive Growth Stocks to Load Up on in Q1
These three defensive growth stocks are excellent options to consider for investors concerned about continued volatility in Q1. 
Via InvestorPlace
2 High-Yielding Dividend Stocks Trading Near 52-Week Lows
These stocks both yield more than 3% right now. 
Via The Motley Fool
3 of the BEST Dividend Growth Stocks
All three of these companies have consistently increased their dividends at a fast pace. 
Via The Motley Fool
Better Buy: Johnson & Johnson or AbbVie?
The healthcare giants are favored by income-oriented investors but have a potentially disruptive year ahead. 
Via The Motley Fool
Tuesday Talk: My Sweet CPI
The street is hoping for sweet January CPI data today and that anticipation pushed stocks higher on Monday. 
Via Talk Markets
The 7 Most Undervalued Dividend Aristocrats to Buy
With so many uncertainties ahead, investors may take comfort in the stability of the most undervalued dividend aristocrats to buy. 
Via InvestorPlace
Large-Cap Biopharmaceuticals: Bearish Sentiment Curbs Buyers
Large cap biopharma stocks are off their highs despite reasonable valuations plus dividends. 
Via Talk Markets
AbbVie Has a Mixed Outlook After Mixed Earnings
AbbVie stock was up after posting a mixed fourth-quarter earnings report, but with the company's patent expiring on Humira, the stock is a hold 
Via MarketBeat
Topics Earnings Intellectual Property
Exposures Financial Intellectual Property
GlycoMimetics Audio Discussion And Analysis With Dan Cohen And Scott Matusow
Dan Cohen and Scott Matusow discuss In this 1:11 audio the upcoming data sets for Glycomimetics. We talk about The Company's platform chemistry in depth, and give our predictions for success/failure of... 
Via Talk Markets
Here's Exactly How AbbVie Stock Can Beat the Market In 2023
Don't think the challenges for Humira doom AbbVie to a sub-par stock performance this year. 
Via The Motley Fool
AbbVie's Humira: The Downfall Won't Be As 'Draconian' As Initially Expected
The company expects Humira sales to fall 37% this year. 
Via Investor's Business Daily
Stock Market Pulls Back As Treasury Yields Jump; Google Dives On AI Flop: Weekly Review
Is this a normal, healthy pullback or the start of something more? 
Via Investor's Business Daily
Danaher, NextEra Energy, Paramount Global, AbbVie And This Mid-Cap ETF On CNBC's 'Final Trades'
On CNBC’s "Halftime Report Final Trades," Shannon Saccocia of Boston Private named Danaher Corporation (NYSE: DHR) as 
Via Benzinga
AbbVie Beats On Q4 Earnings, Skyrizi Sales Grows 76%, Annual Guidance Lags Consensus
 
Via Benzinga
Do Humira Biosimilars Threaten AbbVie's Dividend?
Generic competition will eat at Humira's roughly $20 billion in annual sales. 
Via The Motley Fool
Benzinga's Top Ratings Upgrades, Downgrades For February 10, 2023
 
Via Benzinga
AbbVie Profit Outlook Widely Misses As The U.S. Humira Battle Kicks Off
The company's fourth quarter also came in mixed with lighter-than-expected sales. 
Via Investor's Business Daily
< Previous 1 2 3 4 5 6 7 8 9
...
36 37 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.